|
"yabe d"的相关文件
显示项目 1-5 / 5 (共1页)
1
每页显示[10|25|50]项目
| 國家衛生研究院 |
2025-05-20 |
Accelerating innovation and ensuring the thoughtful withdrawal of lifeline medicines for people living with diabetes in Asia
|
Seino, Y;Yabe, D;Choi, SH;Hsu, CC;Huang, CN;Khasag, A;Tan, K;Ueki, K;Yamada, Y;Akanov, ZA;Kadowaki, T |
| 國家衛生研究院 |
2023-08-31 |
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
|
Vistisen, D; Carstensen, B; Elisabetta, P; Lanzinger, S; Tan, ECH; Yabe, D; Kim, DJ; Sheu, WHH; Melzer-Cohen, C; Holl, RW; Núñez, J; Ha, KH; Halvorsen, S; Langslet, G; Karasik, A; Nyström, T; Niskanen, L; Guleria, S; Klement, R; Carrasco, M; Foersch, J; Shay, C; Koeneman, L; Hoti, F; Farsani, SF; Khunti, K; Zaccardi, F; Subramanian, A; Nirantharakumar, K; EMPRISE EU and East Asia Study Group |
| 臺大學術典藏 |
2020-05-25T02:46:08Z |
Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I–III clinical trials
|
Yabe D.;Yasui A.;Ji L.;Lee M.-K.;Ma R.C.W.;Tien-Jyun Chang;Okamura T.;Zeller C.;Kaspers S.;Lee J.;Kohler S.;Seino Y.; Yabe D.; Yasui A.; Ji L.; Lee M.-K.; Ma R.C.W.; TIEN-JYUN CHANG; Okamura T.; Zeller C.; Kaspers S.; Lee J.; Kohler S.; Seino Y. |
| 臺大學術典藏 |
2020-05-25T02:46:08Z |
Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I–III clinical trials
|
Yabe D.;Yasui A.;Ji L.;Lee M.-K.;Ma R.C.W.;Tien-Jyun Chang;Okamura T.;Zeller C.;Kaspers S.;Lee J.;Kohler S.;Seino Y.; Yabe D.; Yasui A.; Ji L.; Lee M.-K.; Ma R.C.W.; TIEN-JYUN CHANG; Okamura T.; Zeller C.; Kaspers S.; Lee J.; Kohler S.; Seino Y. |
| 中山醫學大學 |
2020 |
Diabetes and COVID-19: IDF perspective in the Western Pacific region
|
Hwang, Y; Khasag, A; Jia, WP; Jenkins, A; Huang, CN; Yabe, D; Kim, DM; Kadowaki, T; Lee, MK |
显示项目 1-5 / 5 (共1页)
1
每页显示[10|25|50]项目
|
